MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

The European Patent Office (EPO) has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières (MSF).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

Americas

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Asia

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

More on this story

Editor's picks

Editor's picks

More features